Human T-Lymphotropic Virus-1/2 Infection in Central Brazil Prisons: A Multicenter Study.
Brazil
high-risk population
human T-lymphotropic virus
prevalence
prisoners
Journal
Frontiers in microbiology
ISSN: 1664-302X
Titre abrégé: Front Microbiol
Pays: Switzerland
ID NLM: 101548977
Informations de publication
Date de publication:
2021
2021
Historique:
received:
12
07
2021
accepted:
20
12
2021
entrez:
7
2
2022
pubmed:
8
2
2022
medline:
8
2
2022
Statut:
epublish
Résumé
Human T-lymphotropic virus (HTLV) infection is endemic in some group populations. Prisoners are at high risk of acquiring HTLV infection mainly due to the environment of closed penal institutions, socioeconomic conditions, and risk behaviors. This study aimed to investigate the prevalence, the occurrence of new cases of HTLV infection after a 1-year follow-up, and circulating subtypes of HTLV-1 among prisoners from twelve closed prisons in Mato Grosso do Sul state, Central Brazil. A total of 1,507 prisoners were randomly enrolled in the cross-sectional study. Out of the 1,507 participants, 1,000 prisoners, susceptible to HTLV infection, were included in the prospective cohort study. In the cross-sectional study, serological evidence of HTLV infection was 0.4% (CI 95%: 0.1-0.7), tested for anti-HTLV antibodies by enzyme-linked immunosorbent assay (ELISA). Three samples were positive for HTLV-1, two samples were positive for HTLV-2, and 1 sample was indeterminate by the Western blot method. The presence of HTLV proviral DNA was detected in all positive samples by amplification of the HTLV
Identifiants
pubmed: 35126323
doi: 10.3389/fmicb.2021.740245
pmc: PMC8815966
doi:
Types de publication
Journal Article
Langues
eng
Pagination
740245Informations de copyright
Copyright © 2022 Melo Bandeira, Moreira Puga, Croda, Pompílio, Amianti, Rocha de Rezende and Coimbra Motta-Castro.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Rev Soc Bras Med Trop. 2000 Jan-Feb;33(1):27-30
pubmed: 10881115
Rev Inst Med Trop Sao Paulo. 2016 Nov 03;58:80
pubmed: 27828621
Eur J Epidemiol. 2003;18(6):583-8
pubmed: 12908726
AIDS Behav. 2008 Jul;12(4 Suppl):S17-24
pubmed: 18500658
Front Microbiol. 2012 Nov 15;3:388
pubmed: 23162541
Virus Evol. 2020 Jul 24;6(2):veaa053
pubmed: 33133639
PLoS One. 2017 Jan 6;12(1):e0169195
pubmed: 28060860
Eur J Epidemiol. 2000;16(11):1043-9
pubmed: 11421474
PLoS One. 2015 Oct 14;10(10):e0139487
pubmed: 26466312
Rev Inst Med Trop Sao Paulo. 2012 May-Jun;54(3):123-9
pubmed: 22634882
Int J Infect Dis. 2020 Jul;96:298-307
pubmed: 32315810
PLoS One. 2017 Feb 3;12(2):e0171303
pubmed: 28158226
J Med Virol. 2017 Aug;89(8):1498-1502
pubmed: 28240367
PLoS Negl Trop Dis. 2021 Jan 28;15(1):e0008923
pubmed: 33507996
Rev Inst Med Trop Sao Paulo. 1998 Jul-Aug;40(4):209-13
pubmed: 9876432
PLoS One. 2019 Aug 22;14(8):e0221265
pubmed: 31437184
J Clin Microbiol. 2017 Sep;55(9):2838-2849
pubmed: 28701419
Braz J Infect Dis. 2018 Nov - Dec;22(6):472-476
pubmed: 30528600
BMC Infect Dis. 2019 May 22;19(1):459
pubmed: 31117977
Hematol Transfus Cell Ther. 2019 Oct - Dec;41(4):310-315
pubmed: 31409582
Cad Saude Publica. 2005 May-Jun;21(3):926-31
pubmed: 15868051
Sci Rep. 2021 Jul 28;11(1):15367
pubmed: 34321555
J Infect Dev Ctries. 2013 Jun 15;7(6):453-67
pubmed: 23771289
Sci Rep. 2019 Oct 14;9(1):14750
pubmed: 31611600
Rev Soc Bras Med Trop. 2008 Mar-Apr;41(2):148-51
pubmed: 18545834
Public Health Rep. 2019 May/Jun;134(1_suppl):8S-14S
pubmed: 31059410
Front Microbiol. 2020 Jun 03;11:1151
pubmed: 32582093
Viruses. 2020 Sep 04;12(9):
pubmed: 32899621
J Med Virol. 2018 Oct;90(10):1651-1657
pubmed: 29797609
Viruses. 2015 Oct 28;7(11):5643-58
pubmed: 26516904
PLoS Negl Trop Dis. 2015 Apr 17;9(4):e0003691
pubmed: 25886507
Int J STD AIDS. 1996 Aug-Sep;7(5):365-9
pubmed: 8894828
J Clin Virol. 2006 Mar;35(3):244-9
pubmed: 16143565